Just-in-time site activation: open a site in two weeks when a patient appears
Instead of opening a trial at fifty hospitals and waiting for patients, keep a network of pre-vetted clinics ready and switch a trial on where a matching patient is found.
A network of community and academic sites holds master agreements, a central IRB, standing budgets and trained staff; when a matched patient is identified (via matching tools or referral), the site is activated for that protocol within 10-14 days. TAPUR and some rare-tumour and biomarker-defined trials have used this model; the idea is to make it the default for biomarker-selected phase 2 and rare-cancer trials and to fund the network as infrastructure.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaPatients are told which trials they qualify for at every treatment decision, in writing
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly.
- IdeaAgree in advance how to borrow evidence between similar rare cancers
Shares Basket, umbrella, and platform trials, American Society of Clinical Oncology (ASCO), Rare and paediatric cancers without markets.
- IdeaA global open trials operating system any hospital can plug into
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly.
- IdeaSimulate eligibility against real-world data before every protocol is locked
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly.
- InstitutionHL7 International
Shares AI trial matching & clinical decision support, American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
- IdeaTrial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Rare and paediatric cancers without markets.
- IdeaEvery payer covers routine care costs for trial participants, in every country
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
- IdeaLay trial navigators funded per centre, evaluated in a randomised trial
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.